This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer

This study has been completed.
Information provided by (Responsible Party):
Xoft, Inc. Identifier:
First received: November 19, 2009
Last updated: July 24, 2012
Last verified: July 2012
Multicenter, non-randomized, feasibility study to evaluate the treatment and assess acute safety of the FDA Cleared Axxent Electronic Brachytherapy System and vaginal applicator for intracavitary vaginal cuff treatment according to the physician's current standard of care.

Condition Intervention
Endometrial Cancer Radiation: brachytherapy Radiation: Xoft Axxent Electronic Brachytherapy System

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility Study Using the Xoft Axxent Electronic Brachytherapy System for the Treatment of Endometrial Cancer

Further study details as provided by Xoft, Inc.:

Primary Outcome Measures:
  • Assess Number of Patients Who Were Able to Complete Treatment Delivery Using the Axxent Electronic Brachytherapy System [ Time Frame: through completion of radiation therapy ]

Secondary Outcome Measures:
  • Assess Acute Safety Outcomes in Patients During and After Vaginal Cuff Brachytherapy Treatment With the Axxent Electronic Brachytherapy System as Incorporated in to the Physician's Current Standard of Practice [ Time Frame: through 3 month post treatment ]
  • Assess Occurence Rate of Toxicities [ Time Frame: through 3 month follow up post treatment ]

Enrollment: 15
Study Start Date: October 2008
Study Completion Date: April 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
endometrial cancer
Patients are treated with electronic brachytherapy for an FDA cleared indication.
Radiation: brachytherapy
Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
Other Names:
  • Electronic
  • Radiation
  • Vaginal cuff
Radiation: Xoft Axxent Electronic Brachytherapy System
21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
Other Names:
  • Radiation
  • therapy
  • electronic


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Most types of endometrial (uterine) cancer Stage I and Stage II (see exclusion criteria below)
  • Post hysterectomy

Exclusion Criteria:

  • Endometrial (uterine) cancer Stage IA Grade 1
  • Scleroderma
  • Collagen vascular disease
  • Active Lupus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01045187

United States, Arizona
Cancer Treatment Services Arizona
Casa Grande, Arizona, United States, 85222
Southwest Oncology Center
Phoenix, Arizona, United States, 85251
United States, California
Beverly Oncology & Imaging Medical Center, Inc
Montebello, California, United States, 90640
United States, Illinois
Swedish Covenant Hospital
Chicago, Illinois, United States, 60625
Little Company of Mary Hospital
Evergreen Park, Illinois, United States, 60805
United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Xoft, Inc.
Principal Investigator: Adam Dickler, MD Little Company of Mary
  More Information

Responsible Party: Xoft, Inc. Identifier: NCT01045187     History of Changes
Other Study ID Numbers: TPR-0209
Study First Received: November 19, 2009
Results First Received: January 24, 2011
Last Updated: July 24, 2012

Keywords provided by Xoft, Inc.:
endometrial cancer
Uterine cancer
electronic brachytherapy

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female processed this record on September 20, 2017